Antineoplastic effects of liposomal siRNA treatment targeting BLIMP1/PRDM1 in primary effusion lymphoma

Disclosures: none

Contributions: GR, IL and PB conceived the study and wrote the manuscript; GR, IL, PB, DV and CQ, performed in vitro experiments and analyzed the results; DB, BR and GT formulated and characterized liposomal carriers for siRNA delivery and analyzed the results; AM, LL, LC-B and MLC performed in vivo and in vitro experiments and analyzed the results; FForghieri, RM, FN, FForni, MAV, AA, LC-B, LP, MLC and ML helped to interpret the data and critically revised the manuscript.